How to diagnose and treat secondary forms of vasculitis

Best Practice and Research: Clinical Rheumatology

Volumn 19, Issue 2 SPEC. ISS., 2005, Pages 321-336

  Luqmani, Raashid Ahmed ^a   Pathare, Sanjay ^a   Kwok fai, Tony Lee ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b YAN CHAI HOSPITAL   (Hong Kong)

Author keywords

Atherosclerosis; Azathioprine; Cryoglobulinaemia; Cyclophosphamide; Drug toxicity; Glucocorticoids; Hepatitis B; Hepatitis C; Human immunodeficiency virus; Immunosuppressive drugs; Systemic lupus erythematosus; Systemic rheumatoid disease; Vasculitis

Indexed keywords

ANTIRHEUMATIC AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; ELASTASE; HEMOPOIETIC GROWTH FACTOR; HEPATITIS B VACCINE; HYDRALAZINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; INTERFERON; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHOTREXATE; MYELOBLASTIN; MYELOPEROXIDASE; PREDNISOLONE; PROPYLTHIOURACIL; TUMOR NECROSIS FACTOR ANTIBODY;

ATHEROSCLEROSIS; BOLUS INJECTION; BONE MARROW TOXICITY; CLINICAL FEATURE; CLINICAL OBSERVATION; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REGIMEN; DRUG MEGADOSE; HEPATITIS B; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; LABORATORY TEST; LIP BIOPSY; MORTALITY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SYNOVITIS; TREATMENT OUTCOME; VASCULITIS;

EID: 17644386488     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2004.11.002     Document Type: Review

References (68)

1. E.G.L. Bywaters Peripheral vascular obstruction in rheumatoid arthritis and its relationship to other vascular lesions Ann Rheum Dis 16 1957 84-103
2. R.A. Luqmani R.A. Watts D.G.I. Scott et al. Treatment of vasculitis in rheumatoid arthritis Ann Med Interne (Paris) 145 1994 566-576
3. J.M. Tuscano G.S. Harris & T.F. Tedder B-lymphocytes contribute to autoimmune disease pathogenesis: Current trends and clinical implications Autoimmun Rev 2 2003 101-108
4. A.E. Voskuyl J.M.W. Hazes A.H. Zwinderman et al. Diagnostic strategy for the assessment of rheumatoid vasculitis Ann Rheum Dis 62 2003 407-413
5. R. Sagal D. Caspi M. Tishler et al. Accelerated nodulosis in vasculitis during methotrexate therapy for rheumatoid arthritis Arthritis Rheum 31 1988 1182-1185
6. D. Baeten F. de Keyser E.M. Veys et al. Tumour necrosis factor alpha independent disease mechanisms in rheumatoid arthritis: A histopathological study on the effect of Infliximab on rheumatoid nodules Ann Rheum Dis 63 2004 489-493
7. D.G.I. Scott & P.A. Bacon Intravenous cyclophosphamide plus methylprednisolone in the treatment of systemic rheumatoid vasculitis Am J Med 76 1984 377-384
8. M.T. Walters & M.I.D. Cawley Combined suppressive drug treatment in severe refractory rheumatoid disease: An analysis of the relative effects of methylprednisolone, cyclophosphamide and sodium aurothiomalate Ann Rheum Dis 47 1988 924-929
9. F.J. Qasim S. Thiru & K. Gillespie Gold and d-penicillamine induce vasculitis and up-regulate mRNA for IL-4 in the Brown Norway rat: support for a role for Th2 cell activity Clin Exp Immunol 108 1997 438-445
10. S. Halevy H. Giryes I. Avinoach et al. Leukocytoclastic vasculitis induced by low-dose methotrexate: In vitro evidence for an immunologic mechanism J Eur Acad Dermatol Venereol 10 1998 81-85
11. A.H.M. Heurkens M.L. Westedt F.C. Breedveld et al. Prednisolone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis Arch Intern Med 151 1991 2249-2254
12. A. Nicholls M.L. Snaith R.N. Maini et al. Controlled trial of azathioprine in rheumatoid vasculitis Ann Rheum Dis 32 1973 589-591
13. R.A. Watts J. Mooney S.E. Lane & D.G. Scott Rheumatoid vasculitis: becoming extinct? Rheumatology 43 2004 920-923
14. R. Flipo A. Janin E. Hachulla et al. Labial salivary gland biopsy assessment in rheumatoid vasculitis Ann Rheum Dis 53 1994 648-652
15. P.A. Bacon & G.D. Kitas The significance of vascular inflammation in rheumatoid arthritis Ann Rheum Dis 53 1994 621-623
16. A.H. Mulder G. Horst M.A. Van et al. Leeuwen Anti-neutrophil cytoplasmic antibodies in rheumatoid arthritis. Characterisation and clinical correlations Arthritis Rheum 36 1993 1054-1060
17. O. Vittecoq F. Jouen-Bades K. Krzanowska et al. Prospective evaluation of the frequency and clinical significance of antineutrophil cytoplasmic and anticardiolipin antibodies in community cases of patients with rheumatoid arthritis Rheumatology 39 2000 481-489
18. S. Wallberg-Jonsson J.T. Cvetkovic K.G. Sundqvist et al. Activation of the immune system and inflammatory activity in relation to markers of athero-phlembotic disease and atherosclerosis in rheumatoid arthritis J Rheum 29 2002 875-882
19. P. Centofanti E. Dirosa L. Deorsola et al. Primary cardiac tumours: early and late results of surgical treatment in 91 patients Ann Thorac Surg 68 1999 1236-1241
20. S.M. Breathnach & G.C. Wells Amyloid vascular disease: Cord-like thickening of muco-cutaneous arteries, intermittent claudication and angina in a case with underlying myelomatosis Br J Dermatol 102 1980 591-595
21. J.C. Jennette D.S. Sheps & D.D. McNeill Exclusively vascular systemic amyloidosis with visceral ischaemia Arch Pathol Lab Med 106 1982 323-327
22. C.L. Rumbaugh R.T. Bergeron H.C.H. Fang & R. McCormick Cerebral angiographic changes in the drug abuse patient Radiology 101 1971 335-344
23. M.M. Boomsma C.A. Stegeman M.J. Van der Leij et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: A prospective study Arthritis Rheum 43 2000 2025-2033
24. H.K. Choi P.A. Merkel J.W. Tervaert et al. Alternating antineutrophil cytoplasmic antibody specificity: Drug-induced vasculitis in a patient with Wegener's granulomatosis Arthritis Rheum 42 1999 384-388
25. K. Chakravarty & P. Merry Systemic vasculitis and atypical infections: Report of two cases Postgrad Med J 75 1999 544-546
26. L. Guillevin F. Lhote P. Cohen et al. Polyarteritis nodosa related to hepatitis-B virus: A prospective study with long-term observation of 41 patients Medicine 74 1995 238-253
27. D. Lavanchy Hepatitis-B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures J Viral Hepat 11 2004 97-107
28. M. Meltzer E.C. Franklin K. Elias et al. Cryoglobulinemia: A clinical and laboratory study. 2. Cryoglobulins with rheumatoid factor activity Am J Med 40 1966 837-847
29. V. Agnello The etiology and pathophysiology of mixed cryo-globulinemia secondary to hepatitis C virus infection Springer Semin Immunopathol 19 1997 111-129
30. J.M. Levey B. Bjornsson B. Banner et al. Mixed cryoglobulinemia in chronic hepatitis C infection: A clinico-pathologic analysis of 10 cases and review of recent literature Medicine 73 1994 53-67
31. R.W. McMurray & K. Elbourne Hepatitis-C virus infection and auto-immunity Semin Arthritis Rheum 26 1997 680-701
32. C.W. Carson D.L. Conn A.J. Czaja et al. Frequency and significance of antibodies to hepatitis C virus in polyarteritis nodosa J Rheumatol 20 1993 304-309
33. P. Lamprecht O. Gutzeit E. Csernok et al. Prevalence of ANCA in mixed cryoglobulinaemia and chronic hepatitis-C virus infection Clin Exp Rheum 21 6 supplement 32S 2003 89-94
34. G.M. Mody F.A. Parke & J.D. Reveille Articular manifestations of human immunodeficiency virus infection Best Pract Res Rheumatol 17 2003 265-287
35. G. Said C. Lacroix-Ciaudo H. Fujimura et al. Peripheral neuropathy of necrotising arteritis: A clinicopathological study Ann Neurol 23 1988 461-465
36. C. Martinelli A. Azzi G. Buffini et al. Cutaneous vasculitis due to human parvovirus B19 in an HIV-infected patient: Report of a case AIDS 11 1997 1891-1893
37. S. Veraldi & G. Rizzitelli Henoch-Schonlein purpura and human parvovirus B19 Dermatology 189 1994 213-214
38. F. Diaz & J. Collazos Glomerulonephritis and Henoch-Schoenlein purpura associated with acute parvovirus B19 infection Clin Nephrol 53 2000 237-238
39. A. Hakim Concurrent Henoch-Schonlein purpura and papular-purpuric gloves-and-socks syndrome Scand J Rheumatol 29 2000 131-132
40. J.J. Lefrere A.M. Courouce J.P. Soulier et al. Henoch-Schonlein purpura and human parvovirus infection Pediatrics 78 1986 183-184
41. G. Nigro M. Zerbini A. Krzysztoflak et al. Active or recent parvovirus B19 infection in children with Kawasaki disease Lancet 343 1994 1260-1261
42. H. Elling A.T. Olsson & P. Elling Human parvovirus and giant cell arteritis: A selective arteritic impact? Clin Exp Rheumatol 18 4 supplement 20 2000 S12-S14
43. S.E. Gabriel M. Espy D.D. Erdman et al. The role of parvovirus B19 in the pathogenesis of giant cell arteritis: A preliminary evaluation Arthritis Rheum 42 1999 1255-1258
44. S.J. Naides Infection with parvovirus B19 Curr Inf Dis Rep 1 1999 273-278
45. A.D. Wagner H.C. Gerard T. Fresemann et al. Detection of Chlamydia pneumoniae in giant cell vasculitis and correlation with the topographic arrangement of tissue-infiltrating dendritic cells Arthritis Rheum 43 2000 1543-1551
46. G. Haugeberg R. Bie & S.A. Nordbo Temporal arteritis associated with Chlamydia pneumoniae DNA detected in an artery specimen J Rheumatol 28 2001 1738-1739
47. M.J. Regan B.J. Wood Y.H. Hsieh et al. Temporal arteritis and Chlamydia pneumoniae: Failure to detect the organism by polymerase chain reaction in ninety cases and ninety controls Arthritis Rheum 46 2002 1056-1060
48. J. Helweg-Larsen B. Tarp N. Obel & B. Baslund No evidence of parvovirus B19, Chlamydia pneumoniae or human herpes virus infection in temporal artery biopsies in patients with giant cell arteritis Rheumatology 41 2002 445-449
49. R. Cimaz & F. Falcini An update on Kawasaki disease Autoimmun Rev 2 2003 258-263
50. D.Y.M. Leung H.C. Meissner & P.M. Schlievert The etiology and pathogenesis of Kawasaki disease: How close are we to an answer? Curr Opin Infect Dis 10 1997 226-232
51. H.C. Meissner & D.Y.M. Leung Superantigens, conventional antigens and etiology of Kawasaki syndrome Pediatr Infect Dis J 19 2000 91-94
52. D.Y.M. Leung P.M. Schlievert & H.C. Meissner The immunopathogenesis and management of Kawasaki syndrome Arthritis Rheum 41 1998 1538-1547
53. B.L. Kotzin D.Y.M. Leung J. Kappler & P. Marrack Superantigens and their potential role in human disease Adv Immunol 54 1993 99-166
54. N.J. Marchette X. Cao S. Kihara et al. Staphylococcal toxic shock syndrome toxin-1, one possible cause of Kawasaki syndrome? In: H. Kato (ed.), Kawasaki Disease 1995 Elsevier New York 149-155
55. M. Teri K. Miwa T. Wiilaims et al. Failure to confirm involvement of staphylococcal toxin in the pathogenesis of Kawasaki disease In: H. Kato (ed.), Kawasaki Disease 1995 Elsevier New York 144-148
56. A. Bamji & R. Salisbury Cytomegalovirus and vasculitis BMJ 1 1978 623-624
57. G. Doherty & J.W. Bradfield Polyarteritis nodosa associated with acute cytomegalovirus infection Ann Rheum Dis 40 1981 419-421
58. P.R. Phinney S. Fligiel Y.J. Bryson & D.D. Porter Necrotising vasculitis in a case of disseminated neonatal herpes simplex infection Arch Pathol Lab Med 106 1982 64-67
59. R.A. Mackenzie G.S. Forbes & W.E. Karnes Angiographic findings in herpes zoster arteritis Ann Neurol 10 1981 458-464
60. G.S. Hoffman & W.A. Frank Infectious mononucleosis, autoimmunity and vasculitis JAMA 242 1979 2735-2736
61. P.L. Meroni A. Tincani N. Sepp et al. Endothelium and the brain in CNS lupus Lupus 12 2003 919-928
62. C. Mawrin A. Brunn C. Rocken & J.M. Schroder Peripheral neuropathy in systemic lupus erythematosus: Pathomorphological features and distribution pattern of matrix metalloproteinases ACTA Neuropathol (Berlin) 105 2003 365-372
63. Y.F. Cheung T.C. Yung S.C. Tam et al. Novel and traditional cardiovascular risk factors in children after Kawasaki disease: implications for premature atherosclerosis J Am Coll Cardiol 43 2004 120-124
64. N. Noto T. Okada M. Yamasuge et al. Non invasive assessment of early progression of atherosclerosis in adolescents with Kawasaki disease and coronary artery lesions Paediatrics 107 2001 1095-1099
65. P.A. Bacon R.J. Stevens D.M. Carruthers et al. Accelerated atherogenesis in autoimmune rheumatic diseases Autoimmun Rev 1 2002 338-347
66. M.B. Urowitz A.A. Bookman B.E. Koehler et al. The bimodal mortality pattern of systemic lupus erythematosus Am J Med 60 1976 221-225
67. L.E. Rohde & R.T. Lee Pathophysiology of atherosclerotic plaque development and rupture: An overview Semin Vasc Med 3 2003 347-354
68. J.J. Li & C.H. Fang Atheroscleritis is a more rational term for the pathological entity currently known as atherosclerosis Med Hypoth 63 2004 100-102